What question did this study set out to answer?

To evaluate the ex vivo effects of two subcutaneous doses of interferon-gamma on neutrophil oxidative capacity, fungal killing, and CD64 expression in patients with chronic granulomatous disease.

May 1, 1997BloodOpen Access

Dose-Dependent Enhancements by Interferon-γ on Functional Responses of Neutrophils From Chronic Granulomatous Disease Patients

View Full Paper

Ask AI

Bookmark

Authors

AÅAnders ÅhlinKarolinska Institutet GEGöran ElinderKarolinska Institutet JPJan PalmbladKarolinska Institutet

Discussion

Member takes

Implication

Randomized double-blind trial demonstrates dose-dependent improvements in neutrophil function in chronic granulomatous disease, suggesting potential benefits of higher interferon-gamma dosing.

Key Points

To evaluate the ex vivo effects of two subcutaneous doses of interferon-gamma on neutrophil oxidative capacity, fungal killing, and CD64 expression in patients with chronic granulomatous disease.
Randomized double-blind trial in 9 patients with chronic granulomatous disease (gp91phox, p47phox, p67phox, or unspecified deficiency) allocated to receive 50 or 100 µg/m² interferon-gamma subcutaneously on 2 consecutive days, alongside an evaluated female X-linked carrier.
Assessed neutrophil oxidative responses, Aspergillus fumigatus hyphae killing, and Fc gammaRI (CD64) expression pre-treatment and on days 1, 3, 8, and 18 post-treatment.
Killing of Aspergillus fumigatus hyphae increased from near zero baseline to 36% above pre-treatment levels on day 3 in the 100 µg/m² high-dose group versus 17% in the 50 µg/m² low-dose group.
Neutrophil Fc gammaRI (CD64) expression peaked on day 1, rising 3.7-fold in the high-dose group compared to 2.3-fold in the low-dose group.
Oxidative capacity improved in only select patients across disease subtypes, whereas the hyperlyonized carrier displayed marked improvements in both oxidative response and fungal killing.

Cite This Study

Åhlin et al. (1997) studied this question.

synapsesocial.com/papers/6a815e9b046b5fb0cc649ae2 https://doi.org/10.1182/blood.v89.9.3396

View Full Paper

Ask AI

Bookmark

Implication

Randomized double-blind trial demonstrates dose-dependent improvements in neutrophil function in chronic granulomatous disease, suggesting potential benefits of higher interferon-gamma dosing.

Dose-Dependent Enhancements by Interferon-γ on Functional Responses of Neutrophils From Chronic Granulomatous Disease Patients

Discussion

Member takes

Implication

Key Points

Cite This Study

Dose-Dependent Enhancements by Interferon-γ on Functional Responses of Neutrophils From Chronic Granulomatous Disease Patients

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider